OBJECTIVE: To assess the effects of NET on depression and analyze changes in serum inflammatory factors.
METHODS: This retrospective study enrolled 140 patients undergoing treatment for depression between May 2017 and June 2022, the observation group that received a combination of mindfulness-based stress reduction (MBSR) and NET treatment (n = 70) and the control group that only received MBSR therapy (n = 70). The clinical effectiveness of the treatment was evaluated by assessing various factors, including the Hamilton Depression Scale (HAMD)-17, self-rating idea of suicide scale (SSIOS), Pittsburgh Sleep Quality Index (PSQI), and levels of serum inflammatory factors before and after 8 wk of treatment. The quality of life scores between the two groups were compared. Comparisons were made using t and χ2 tests.
RESULTS: After 8 wk of treatment, the observation group exhibited a 91.43% overall effectiveness rate which was higher than that of the control group which was 74.29% (64 vs 52, χ2 = 7.241; P < 0.05). The HAMD, SSIOS, and PSQI scores showed a significant decrease in both groups. Moreover, the observation group had lower scores than the control group (10.37 ± 2.04 vs 14.02 ± 2.16, t = 10.280; 1.67 ±0.28 vs 0.87 ± 0.12, t = 21.970; 5.29 ± 1.33 vs 7.94 ± 1.35, t = 11.700; P both < 0.001). Additionally, there was a notable decrease in the IL-2, IL-1β, and IL-6 in both groups after treatment. Furthermore, the observation group exhibited superior serum inflammatory factors compared to the control group (70.12 ± 10.32 vs 102.24 ± 20.21, t = 11.840; 19.35 ± 2.46 vs 22.27 ± 2.13, t = 7.508; 32.25 ± 4.6 vs 39.42 ± 4.23, t = 9.565; P both < 0.001). Moreover, the observation group exhibited significantly improved quality of life scores compared to the control group (Social function: 19.25 ± 2.76 vs 16.23 ± 2.34; Emotions: 18.54 ± 2.83 vs 12.28 ± 2.16; Environment: 18.49 ± 2.48 vs 16.56 ± 3.44; Physical health: 19.53 ± 2.39 vs 16.62 ± 3.46; P both < 0.001) after treatment.
CONCLUSIONS: MBSR combined with NET effectively alleviates depression, lowers inflammation (IL-2, IL-1β, and IL-6), reduces suicidal thoughts, enhances sleep, and improves the quality of life of individuals with depression.
目的:探讨NET对抑郁症患者的治疗作用及血清炎症因子的变化。
方法:这项回顾性研究纳入了2017年5月至2022年6月期间接受抑郁症治疗的140例患者,观察组接受基于正念的压力减少(MBSR)和NET治疗(n=70),对照组仅接受MBSR治疗(n=70)。通过评估各种因素来评估治疗的临床有效性,包括汉密尔顿抑郁量表(HAMD)-17、自杀自评量表(SSIOS)、匹兹堡睡眠质量指数(PSQI)治疗8周前后血清炎症因子水平。比较两组患者的生活质量评分。使用t和χ2检验进行比较。
结果:治疗8周后,观察组总有效率为91.43%,高于对照组的74.29%(64vs52,χ2=7.241,P<0.05)。HAMD,SSIOS,两组的PSQI评分均显著下降。此外,观察组得分低于对照组(10.37±2.04vs14.02±2.16,t=10.280;1.67±0.28vs0.87±0.12,t=21.970;5.29±1.33vs7.94±1.35,t=11.700;均P<0.001)。此外,IL-2,IL-1β显着下降,两组治疗后IL-6水平变化。此外,观察组血清炎症因子水平优于对照组(70.12±10.32vs102.24±20.21,t=11.840;19.35±2.46vs22.27±2.13,t=7.508;32.25±4.6vs39.42±4.23,t=9.565,P均<0.001)。此外,与对照组相比,观察组的生活质量评分显着提高(治疗后社会功能:19.25±2.76vs16.23±2.34;情绪:18.54±2.83vs12.28±2.16;环境:18.49±2.48vs16.56±3.44;身体健康:19.53±2.39vs16.62±3.46;P均<0.001)。
结论:MBSR联合NET可有效缓解抑郁症,降低炎症(IL-2,IL-1β,和IL-6),减少自杀念头,增强睡眠,改善抑郁症患者的生活质量。